Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Eli Lilly launches oral weight-loss pill Foundayo in UK
2+ hour, 18+ min ago (168+ words) Aug 24 (Reuters) – Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first country in Europe where the treatment is available. • The pill, known chemically as…...
Hope for cancer patients as scientists report breakthrough in personalised cancer vaccines | Nigeria
8+ hour, 2+ min ago (531+ words) Merck and Moderna said the vaccine helped prevent the return and spread of melanoma in a large trial involving more than 1,000 patients. The patients had localised tumours that had been surgically removed but were considered to have a high risk…...
Celltrion and Samsung Bioepis are in full swing over the biosimilar (biopharmaceutical generic drug).. - MK
46+ min ago (520+ words) Celltrion and Samsung Bioepis are in full swing over the biosimilar (biopharmaceutical generic drug) market of the blockbuster immuno-cancer drug Keytruda, which recorded $31.7 billion (about 44 trillion won) in global sales last year. Celltrion announced on the 24th that it has applied…...
Celltrion files for domestic approval of Keytruda biosimilar CT-P51
2+ hour, 31+ min ago (229+ words) Celltrion said Monday it has filed for domestic product approval of CT-P51, a biosimilar of Keytruda (pembrolizumab), the world's best-selling immunotherapy, with the Ministry of Food and Drug Safety. The filing covers Keytruda's major indications, including non-small cell lung cancer,…...
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
1+ hour, 2+ min ago (172+ words) 24 August 2026 | Monday | News AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline. B7-H3 is highly expressed in a broad…...
Avecho moves to deepen global partnering push as CBD insomnia program advances
1+ hour, 11+ min ago (102+ words) PharmaDispatch Avecho moves to deepen global partnering push as CBD insomnia program advances Avecho chief executive Dr Paul Gavin said the timing reflected the program's growing commercial relevance as it approaches a critical clinical and regulatory stage. … July recommendations across…...
s???pore-authorizes-use-of-molnupiravir-for-covid-19-patients
2+ hour, 33+ min ago (9+ words) s’pore-authorizes-use-of-molnupiravir-for-covid-19-patients The Independent Singapore News © The Independent Singapore...
Rare Disease treatment - 2HD
1+ hour, 19+ min ago (7+ words) Rare disease breakthrough life changing result 2HD...
Leading immunologist recognised for breakthrough discovery that could transform patient care in severe respiratory viral infections??? News Hub
2+ hour, 23+ min ago (797+ words) Issued: Monday 24 August 2026 For two decades, Professor Katherine Kedzierska has been searching for the answer to one of medicine's most important questions: why do some people recover quickly from respiratory viruses while others become critically ill? Yet despite decades of…...
Eli Lilly launches oral weight-loss pill Foundayo in UK | WSAU News/Talk 550 AM · 99.9 FM | Wausau, Stevens Point
2+ hour, 20+ min ago (168+ words) Aug 24 (Reuters) – Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first country in Europe where the treatment is available. • The pill, known chemically as…...